Sharp collapse masks intact long-term thesis; cell ramp critical

PAT crashed to ₹5.4 Cr (1% margin), lowest in years despite selectivity

Tool move-in, equipment install underway; inspection planned but not assured

Order book confirmed at 6.35 GW (~₹8,200 Cr), 132% of current 4.8 GW module capacity

Iran war since Feb 20; customer delays, ALMM uncertainty ongoing into Q2; no resolution cited

Mechanism sound but delayed; no timeline for when margin uplift hits; Q1 already at 1% PAT

Prior call suggested faster ramp; now inspection is gate. Expected 80% utilization by Q4 FY27, not sooner.

ALMM-1 vs ALMM-2 uncertainty, geopolitical drag (Iran war Feb 20) caused customer deferrals into Q2. Q1 margin (1% PAT) far below 6–7% target.

New orders secured: ₹138 Cr (Jul 2026, delivery by Dec 2026) + ₹400 Cr (Aug 11, 2026, delivery by Mar 2027).

Current debt ₹1,250 Cr; net debt expected to peak ₹2,200–2,400 Cr by FY28. Capex incurred ₹1,000 Cr so far, ~₹3,500 Cr total.

Currently 4–5%; targeting 7–8% this year, 15% by FY28 (Melcon transformer, power electronics, storage, B2C).

Cell ramp (Sept ALMM-2 inspection, Q3 production). Encapsulant capacity increase to 5 GW (currently 2 GW). Supply chain diversification away from China. Target 'high-double-digit' margins post-cell.

Ramp-up by end Aug/early Sept. ALMM-2 inspection Sept. Full ramp in 3 months = 80% utilization by Q4 FY27 (2.4 GW cell = ~200 MW/month).

Yes. ALMM-2 postponed to Jan 1 due to cell shortage; high demand for domestic ALMM-2 cells. Cell manufacturing = significant EBITDA & bottom-line increase, 'high-double-digits' but specific number withheld.

No cell manufacturing (module-only = crowded). Geopolitical impact (commodity, freight, forex). Customer delays (ALMM-1 vs ALMM-2 uncertainty). Selective order execution to avoid unprofitable deals. Margins should improve Q2 onwards if geopolitical improves & volumes rise.

~70% utility, 30% C&I. ~30% DCR orders. On pricing: C&I ~30% fixed, utility ~30% variable + 70% fixed. DCR margins ~18–20% on cells.

Current debt ₹1,250 Cr. Net debt expected to peak ₹2,200–2,400 Cr. Phase 1 capex ~₹1,850 Cr (2.4 GW cell + 4 GW module), Phase 2 ~₹1,600–1,700 Cr (3.6 GW cell). Total ~₹3,500 Cr. ₹1,000 Cr incurred so far.

Iran war (Feb 20) raised input costs, forcing projects to defer. Force majeure notices issued. Extension expectations softened demand. Tariff cliff from June 30 to July 1 created uncertainty. Projects in wait-and-watch May–June.

C&I ~30% fixed. Utility ~30% variable, 70% fixed. [Implies utility has better pass-through.]

3.5–4 GW sales. Revenue ~₹6,000 Cr. EBITDA ~12%. PAT margin 6–7%. Non-module business target 7–8% this year, 15% by FY28.

Govt vision: reduce China dependency. Build integrated ecosystem (module → cell → ingot/wafer). Expand ancillaries (transformers, inverters, storage). Target 50% of project cost vs current 25%. Phase 3: 6 GW ingot/wafer by FY29.

Demand structural (57 GW last year). Electric vehicles, data centers, AI drive growth. Target 70–80 GW market, eventually 100 GW + replacement. Well positioned. Module + cell + backward integration = growth path.

Melcon acquired mid-Q1. Transformer market ₹30K Cr now → ₹55K Cr by 2031. Target 8–10% market share. Planning ₹1,000–1,500 Cr business in 3–4 years. Expansion announcement coming soon.

₹8,200 Cr.

DCR orders in orderbook assume internal manufacturing. Bought-cell orders are spot, not in book. Internal cell DCR margins: 18–20%.

Difficult to comment now; maybe Q3. Geopolitical must improve. Not enough cell capacity. Large utility projects (18–24 mo cycle) tendered Dec–present; real demand FY28 from utility, C&I, KUSUM, retail. FY28 will be 'milestone year'.

Orderbook typically 12–18 mo execution. Retail ~20% of monthly sales, not in orderbook.

Reaffirmed but under pressure. Q1 executed only 334 MW sales; need 875–1,000 MW avg per quarter for ₹6K Cr. Cell ramp Q3 is key trigger.

Q1 delivered 8.33% EBITDA, 1% PAT. To hit 12% EBITDA & 6–7% PAT for year, Q2–Q4 must average ~13% EBITDA, 9–10% PAT. Implied by cell ramp (Sep inspection gate). High execution risk.

Incurred ₹1,000 Cr so far. Aligns with prior FY27 ₹1,700 Cr + FY28 ₹1,800–2,000 Cr guidance. On track.

ALMM-2 inspection Sept 2026 is gate. Ramp timeline (3 months to 80% utilization Q4) aggressive. Equipment installation still in progress. Inspection failure or delay derails margin recovery plan.

Q1 PAT only ₹5.4 Cr (1% margin) despite 'selective order execution'. Module market commoditized. Geopolitical headwind (commodity, freight, forex) ongoing. FY27 6–7% PAT target may be unachievable without cell margins.

ALMM-1 vs ALMM-2 tariff cliff (June 30 2026 → Jan 1 2027 postponement) caused significant deferral. Large utility projects (18–24 mo cycle) deferred post-war (Feb 20). Real demand inflection expected only FY28.

Iran war (Feb 20) elevated commodity prices, logistics costs, forex volatility. Input costs for projects rose; project economics deteriorated. No timeline for resolution cited.

Capex ~₹3,500 Cr for Phase 1+2. Current debt ₹1,250 Cr; net debt expected to peak ₹2,200–2,400 Cr. If Phase 3 (ingot/wafer) added, leverage could rise further. Margin shortfall makes debt servicing harder.